Press release

[PRESS RELEASE] UAE business leaders introduce Emirati startups to Israelis at OurCrowd-Emirates Angels Event

[PRESS RELEASE] UAE business leaders introduce Emirati startups to Israelis at OurCrowd-Emirates Angels Event

Oct 13, 2020 |

Jerusalem & Abu Dhabi, Oct. 13, 2020 – OurCrowd, the world’s largest global venture investing platform and Emirates Angels Investors Association, the leading Emirati angel investment network, today held an online event which gave Israeli investors and entrepreneurs their first glimpse of the tech opportunities available in the United Arab Emirates.  UAE Tech Investment Landscape: Introduction for the Israeli Ecosystem, broke records with over 2,000 registrants who were able to hear from some of the Emirates’ top business leaders and officials talking directly to Israelis for the first time. Read more...

Read More
[PRESS RELEASE] OURCROWD & ABDULLAH SAEED AL NABOODAH CREATE PARTNERSHIP TO DEVELOP TECH INVESTMENT TIES BETWEEN GULF REGION & ISRAEL

[PRESS RELEASE] OURCROWD & ABDULLAH SAEED AL NABOODAH CREATE PARTNERSHIP TO DEVELOP TECH INVESTMENT TIES BETWEEN GULF REGION & ISRAEL

Oct 6, 2020 |

Jerusalem/Dubai, Oct. 6, 2020 – OurCrowd, the world’s largest global venture investing platform, today signed a memorandum of understanding with Phoenix, a business development company, to increase business and tech ties between Israel and the United Arab Emirates. This is the first announced alliance between a top-ranked UAE corporation and a major Israeli venture investment firm. Read more...

Read More
[PRESS RELEASE] SIGHT DIAGNOSTICS RAISES $71M TO ACCELERATE GLOBAL EXPANSION OF ITSFDA 510(K) CLEARED, CE MARKED FINGER-PRICK BLOOD ANALYZER

[PRESS RELEASE] SIGHT DIAGNOSTICS RAISES $71M TO ACCELERATE GLOBAL EXPANSION OF ITSFDA 510(K) CLEARED, CE MARKED FINGER-PRICK BLOOD ANALYZER

Aug 7, 2020 |

Tel Aviv, Israel (August 5, 2020) – Sight Diagnostics, the company behind the first FDA-cleared direct-from-fingerstick Complete Blood Count (CBC) analyzer, announced today it has raised $71 million in Series D funding with participation from Koch Disruptive Technologies, Longliv Ventures and OurCrowd. This new round brings Sight’s total funding to more than $124 million and will support the expansion of Sight’s commercial operations globally and advance Sight’s R&D into the detection of additional diseases as well as biomarkers indicating COVID-19 severity. Read more...

Read More
PRESS RELEASE: Sight Diagnostics Raises $71M To Accelerate Global Expansion of itsFDA 510(k) Cleared, CE Marked Finger-prick Blood Analyzer

PRESS RELEASE: Sight Diagnostics Raises $71M To Accelerate Global Expansion of itsFDA 510(k) Cleared, CE Marked Finger-prick Blood Analyzer

Aug 6, 2020 |

Sight Diagnostics Raises $71M To Accelerate Global Expansion of its FDA 510(k) Cleared, CE Marked Finger-prick Blood Analyzer The investment from Koch Disruptive Technologies, Longliv Ventures, a member of the CK Hutchison Holdings and OurCrowd will fuel Sight’s R&D into the automated identification and detection of diseases Tel Aviv, Israel (August 5, 2020) – Sight DiagnosticsⓇ, the company behind the first FDA-cleared direct-from-fingerstick Complete Blood Count (CBC) analyzer, announced today it has raised $71 million in Series D funding with participation from Koch Disruptive Technologies, Longliv Ventures and OurCrowd. This new round brings Sight’s total funding to more than $124 million and will support the expansion of Sight’s commercial operations globally and advance Sight’s R&D into the detection of additional diseases as well as biomarkers indicating COVID-19 severity. “We firmly believe that Sight’s method of using machine vision to analyze blood is a significant leap forward from the current alternative in healthcare,” said Chase Koch, President of Koch Disruptive Technologies. “Not only is the company bringing truly innovative solutions to the blood diagnostics industry, it is also driving a...

Read More